Published in J Am Soc Nephrol on December 23, 2015
Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling. Oncogene (2017) 0.75
Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts. Oncotarget (2016) 0.75
Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. J Diabetes Investig (2017) 0.75
Hyperhomocysteinemia in ApoE-/- Mice Leads to Overexpression of Enhancer of Zeste Homolog 2 via miR-92a Regulation. PLoS One (2016) 0.75
Genetic and epigenetic regulation of intestinal fibrosis. United European Gastroenterol J (2016) 0.75
miR-202 Diminishes TGFbeta Receptors and Attenuates TGFbeta1-induced EMT in Pancreatic Cancer. Mol Cancer Res (2017) 0.75
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
The Polycomb complex PRC2 and its mark in life. Nature (2011) 11.97
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev (2004) 7.89
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol (2004) 5.43
Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int (2006) 4.87
Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med (2010) 4.76
Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell (2008) 4.44
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med (2010) 3.60
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev (2004) 3.14
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A (2012) 3.03
TGF-beta in renal injury and disease. Semin Nephrol (2007) 2.65
Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med (2005) 2.61
Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem (2000) 2.58
A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol (2006) 2.57
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Polycomb group protein-mediated repression of transcription. Trends Biochem Sci (2010) 2.37
A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int (2010) 2.32
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene (2008) 2.31
Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) (2005) 2.23
MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology (2009) 2.17
Mechanisms of disease: Fibroblasts--a new look at an old problem. Nat Clin Pract Nephrol (2006) 2.14
Cancer epigenomics: beyond genomics. Curr Opin Genet Dev (2012) 2.11
Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest (2014) 2.07
Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem (2003) 1.97
Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol (1996) 1.85
Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol (2011) 1.76
Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest (2000) 1.68
PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest (2008) 1.68
TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol (2009) 1.66
Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol (2009) 1.53
Isolation and developmental expression analysis of Enx-1, a novel mouse Polycomb group gene. Mech Dev (1996) 1.45
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer (2010) 1.42
TGF-beta signal transduction in chronic kidney disease. Front Biosci (Landmark Ed) (2009) 1.41
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther (2014) 1.37
TGF-β/Smad signaling in kidney disease. Semin Nephrol (2012) 1.36
Transforming growth factor-β and the progression of renal disease. Nephrol Dial Transplant (2013) 1.32
Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int (2002) 1.24
Polycomb target genes are silenced in multiple myeloma. PLoS One (2010) 1.21
EZH2: not EZHY (easy) to deal. Mol Cancer Res (2014) 1.20
Transforming growth factor beta signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses. Cancer Res (2007) 1.18
Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol (2009) 1.13
Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int (2014) 1.13
Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol (2011) 1.07
Genomics and epigenomics of renal cell carcinoma. Semin Cancer Biol (2012) 1.05
Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res (2011) 1.04
Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol (2009) 1.03
Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer (2012) 1.01
Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin Cancer Res (2012) 0.95
Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cell Res (2013) 0.94
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. Mediators Inflamm (2007) 0.92
Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. J Neurooncol (2010) 0.92
Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells. Oncogenesis (2014) 0.91
Epigenomics of cancer - emerging new concepts. Biochimie (2012) 0.90
A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. FASEB J (2014) 0.89
PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res (2000) 0.86
Epigenetics of progression of chronic kidney disease: fact or fantasy? Semin Nephrol (2013) 0.86
TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis. Kidney Int (2007) 0.83
Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis (2012) 0.83
Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis. Kidney Int Suppl (2011) (2014) 0.83
Transforming growth factor-beta production during the development of renal fibrosis in rats with subtotal renal ablation. Int J Exp Pathol (1996) 0.82
Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™. Eur J Pharm Sci (2015) 0.81
Mutant MMP-9 and HGF gene transfer enhance resolution of CCl4-induced liver fibrosis in rats: role of ASH1 and EZH2 methyltransferases repression. PLoS One (2014) 0.81
Evidence for the involvement of epigenetics in the progression of renal fibrogenesis. Nephrol Dial Transplant (2013) 0.80
Ubiquitination and regulation of Smad7 in the TGF-β1/Smad signaling of aristolochic acid nephropathy. Toxicol Mech Methods (2015) 0.78
Extracellular signal-regulated kinase-dependent interstitial macrophage proliferation in the obstructed mouse kidney. Nephrology (Carlton) (2008) 0.78
Epigenetics: Marked for success. Nature (2012) 0.76
Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS One (2013) 1.26
Suramin alleviates glomerular injury and inflammation in the remnant kidney. PLoS One (2012) 0.85
Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy. J Pharmacol Exp Ther (2011) 0.84
Autophagy in Chronic Kidney Diseases. Kidney Dis (Basel) (2016) 0.79
Epigenetic Regulations in Diabetic Nephropathy. J Diabetes Res (2017) 0.75
Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis. Oncotarget (2016) 0.75
Podocyte Autophagy: A Potential Therapeutic Target to Prevent the Progression of Diabetic Nephropathy. J Diabetes Res (2017) 0.75
Nintedanib,a triple tyrosine kinase inhibitor,attenuates renal fibrosis in chronic kidney disease. Clin Sci (Lond) (2017) 0.75
Histone deacetylase 6 inhibition counteracts the epithelial-mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis. Oncotarget (2017) 0.75